Every major drug patent expiration triggers a predictable downstream event: the originator company races to defend margin, and a dozen […]

The LOE Wave Nobody in Equipment Sales Is Talking About Between 2024 and 2029, roughly $130 billion worth of branded

The Revenue Cliff Is Real, and So Is Your Window Every year, billions of dollars in branded pharmaceutical revenue evaporate

The Geography Problem Nobody Warns You About The patent expired. You know the date, you have it in your spreadsheet,

The race for biosimilar first-mover advantage is decided long before the FDA approves a single molecule. It is decided in

The Question That Drives a $200 Billion Market Every time a pharmacist hands a patient a generic substitute for a

How the Hybrid Regulatory Strategy Cuts Risk, Compresses Timelines, and Unlocks Pipeline Value for Pharmaceutical Executives Why Most Drug Developers

A forward-looking analysis of the Inflation Reduction Act’s structural impact on U.S. pharmaceutical economics The Price Is Wrong: What the

Pharmaceutical companies spend decades constructing legal fortresses around their best-selling drugs. They file dozens of secondary patents on minor formulation